Advertisement

Der Schmerz

, Volume 33, Issue 2, pp 156–164 | Cite as

Ketamin in der Schmerztherapie

  • Rae Frances BellEmail author
  • Eija Anneli Kalso
Pain Clinical Updates

Hintergrund

Pharmakologische Grundlagen und Wirkmechanismen von Ketamin

Ketamin wird häufig als Analgetikum in der Notfallmedizin und als perioperatives Adjuvans genutzt. Darüber hinaus findet es als Drittlinienadjuvans bei opioidresistentem Schmerz in der Palliativmedizin und bei therapieresistentem chronischem Nichttumorschmerz Verwendung. Seit Neuerem wird Ketamin vermehrt bei Major-Depression und anderen affektiven Störungen eingesetzt.

Ketamin ist ein Phencyclidin-Derivat und wurde in den 1960er-Jahren als Anästhetikum entwickelt. Die wichtigsten pharmakologischen Eigenschaften sind durch die Funktion als nichtkompetitiver N‑Methyl-D-Aspartat(NMDA)-Rezeptor-Antagonist bedingt, und die analgetische Wirkung in subanästhetischer Dosis geht vermutlich vorwiegend auf den NMDA-Rezeptor-Antagonismus im Gehirn und Rückenmark zurück [33]. Der NMDA-Rezeptor ist von Bedeutung für Lernprozesse, Gedächtnis und synaptische Plastizität. Im Zusammenhang mit Schmerz ist er an der Verstärkung von...

Ketamine for pain management

Notes

Interessenkonflikt

R.F. Bell gibt an, dass kein Interessenkonflikt besteht. E.A. Kalso gibt an, unabhängig von der vorliegenden Arbeit persönliche Honorare von Pierre Fabre und Grünenthal erhalten zu haben.

Übersetzung: Ansgar Schlichting

Literatur

  1. 1.
    Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH (2016) Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety 33:689–697CrossRefGoogle Scholar
  2. 2.
    Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, Mathew SJ, Mathalon DH (2017) Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment. Biol Psychiatry Cogn Neurosci Neuroimaging 2:566–574CrossRefGoogle Scholar
  3. 3.
    Amr YM (2010) Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician 13:245–249PubMedGoogle Scholar
  4. 4.
    Assouline B, Tramèr MR, Kreienbühl L, Elia N (2016) Benefit and harm of adding ketamine to an opioid in a patient-controlled analgesia device for the control of postoperative pain: systematic review and meta-analyses of randomized controlled trials with trial sequential analyses. Pain 157:2854–2864CrossRefGoogle Scholar
  5. 5.
    Available at: http://ketamineclinicsdirectory.com. Accessed March 27, 2018.
  6. 6.
    Azari P, Lindsay DR, Briones D, Clarke C, Buchheit T, Pyati S (2012) Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS Drugs 26:215–228CrossRefGoogle Scholar
  7. 7.
    Bell RF (1999) Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 83:101–103CrossRefGoogle Scholar
  8. 8.
    Bell RF, Dahl JB, Moore RA, Kalso EA (2006) Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd004603.pub2 CrossRefPubMedGoogle Scholar
  9. 9.
    Bell RF, Eccleston C, Kalso EA (2017) Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.cd003351.pub3 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bell RF, Jaksch W, Kalso EA (2014) Interpreting the evidence: reply to Spruyt et al. J Pain Symptom Manage 47:e2–e4CrossRefGoogle Scholar
  11. 11.
    Bell RF, Moore RA (2010) Intravenous ketamine for CRPS: making too much of too little? Pain 150:10–11CrossRefGoogle Scholar
  12. 12.
    Bonnet U (2015) Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction. J Psychoactive Drugs 47:276–285CrossRefGoogle Scholar
  13. 13.
    Bredlau AL, Thakur R, Korones DN, Dworkin RH (2013) Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. Pain Med 14:1505–1517CrossRefGoogle Scholar
  14. 14.
    Brinck ECV, Tiippana E, Heesen M, Bell RF, Straube S, Moore RAS, Kontinen V (2018) Perioperative intravenous ketamine for acute postoperative pain. Cochrane Database Syst RevGoogle Scholar
  15. 15.
    Dale O, Somogyi AA, Li Y, Sullivan T, Shavit Y (2012) Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg 115:934–943CrossRefGoogle Scholar
  16. 16.
    Elia N, Tramèr MR (2005) Ketamine and postoperative pain—a quantitative systematic review of randomised trials. Pain 113:61–70CrossRefGoogle Scholar
  17. 17.
    Grégoire MC, MacLellan DL, Finley GA (2008) A pediatric case of ketamine associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B, et al: ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69:810–812, 2007). Urology 71:1232–1233CrossRefGoogle Scholar
  18. 18.
    Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, Spruyt O, Rowett D, Currow DC (2012) Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 30:3611–3617CrossRefGoogle Scholar
  19. 19.
    Hocking G, Cousins MJ (2003) Ketamine in chronic pain management: an evidence-based review. Anesth Analg 97:1730–1739CrossRefGoogle Scholar
  20. 20.
    Karpinski N, Dunn J, Hansen L, Masliah E (1997) Subpial vacuolar myelopathy after intrathecal ketamine: report of a case. Pain 73:103–105CrossRefGoogle Scholar
  21. 21.
    Laskowski K, Stirling A, McKay WP, Lim HJ (2011) Asystematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth 58:911–923CrossRefGoogle Scholar
  22. 22.
    Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G (2002) The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg 94:1263–1269CrossRefGoogle Scholar
  23. 23.
    Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Coller JK, Hutchinson MR, Currow DC, Somogyi AA (2015) CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharmacol 80:276–284CrossRefGoogle Scholar
  24. 24.
    Lilius TO, Jokinen V, Neuvonen MS, Niemi M, Kalso EA, Rauhala PV (2015) Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. Br J Pharmacol 172:2799–2813CrossRefGoogle Scholar
  25. 25.
    Lilius T, Kangas E, Niemi M, Rauhala P, Kalso E (2018) Ketamine and norketamine attenuate oxycodone tolerance markedly less than that of morphine: from behaviour to drug availability. Br J Anaesth 120:818–826CrossRefGoogle Scholar
  26. 26.
    Lilius TO, Viisanen H, Jokinen V, Niemi M, Kalso EA, Rauhala PV (2018) Interactions of (2S,6S;2R,6R)-hydroxynorketamine, a secondary metabolite of (R,S)-ketamine, with morphine. Basic Clin Pharmacol Toxicol 122:481–488CrossRefGoogle Scholar
  27. 27.
    Liu SYW, Ng SKK, Tam YH, Yee SCH, Lai FPT, Hong CYL, Chiu PWY, Ng EKW, Ng CF (2017) Clinical pattern and prevalence of upper gastrointestinal toxicity in patients abusing ketamine. J Dig Dis 18:504–510CrossRefGoogle Scholar
  28. 28.
    Lu W, Wang L, Wo C, Yao J (2016) Ketamine attenuates osteoarthritis of the knee via modulation of inflammatory responses in a rabbit model. Mol Med Rep 13:5013–5020CrossRefGoogle Scholar
  29. 29.
    Mayell A, Natusch D (2009) Anosmia—a potential complication of intranasal ketamine. Anaesthesia 64:457–458CrossRefGoogle Scholar
  30. 30.
    McNicol ED, Schumann R, Haroutounian S (2014) A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain. Acta Anaesthesiol Scand 58:1199–1213CrossRefGoogle Scholar
  31. 31.
    Mercadante S, Arcuri E, Tirelli W, Casuccio A (2000) Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 20:246–252CrossRefGoogle Scholar
  32. 32.
    Michelet D, Brasher C, Horlin AL, Bellon M, Julien-Marsollier F, Vacher T, Pontone S, Dahmani S (2018) Ketamine for chronic non-cancer pain: a metaanalysis and trial sequential analysis of randomized controlled trials. Eur J Pain 22:632–646CrossRefGoogle Scholar
  33. 33.
    Mion G, Villevieille T (2013) Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 19:370–380CrossRefGoogle Scholar
  34. 34.
    Mitchell AC (1999) Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliat Med 13:427–428CrossRefGoogle Scholar
  35. 35.
    Mitchell AC, Fallon MT (2002) A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial. Pain 97:275–281CrossRefGoogle Scholar
  36. 36.
    Moyse DW, Kaye AD, Diaz JH, Qadri MY, Lindsay D, Pyati S (2017) Perioperative ketamine administration for thoracotomy pain. Pain Physician 20:173–184PubMedGoogle Scholar
  37. 37.
    Murphy EJ (2005) Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 33:311–322CrossRefGoogle Scholar
  38. 38.
    Noppers IM, Niesters M, Aarts LP, Bauer MC, Drewes AM, Dahan A, Sarton EY (2011) Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain 152:2173–2178CrossRefGoogle Scholar
  39. 39.
    Olofsen E, Noppers I, Niesters M, Kharasch E, Aarts L, Sarton E, Dahan A (2012) Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology 117:353–364CrossRefGoogle Scholar
  40. 40.
    Oshima E, Tei K, Kayazawa H, Urabe N (1990) Continuous subcutaneous injection of ketamine for cancer pain. Can J Anaesth 37:385–386CrossRefGoogle Scholar
  41. 41.
    Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI (2016) Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet 55:1059–1077CrossRefGoogle Scholar
  42. 42.
    Pendi A, Field R, Farhan SD, Eichler M, Bederman SS (2018) Perioperative ketamine for analgesia in spine surgery: a meta-analysis of randomized controlled trials. Spine (Phila Pa 1976) 43:E299–E307CrossRefGoogle Scholar
  43. 43.
    Rigo FK, Trevisan G, Godoy MC, Rossato MF, Dalmolin GD, Silva MA, Menezes MS, Caumo W, Ferreira J (2017) Management of neuropathic chronic pain with methadone combined with ketamine: a randomized, double blind, active-controlled clinical trial. Pain Physician 20:207–215PubMedGoogle Scholar
  44. 44.
    Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M (2009) Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 147:107–115CrossRefGoogle Scholar
  45. 45.
    Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A (2009) Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain 145:304–311CrossRefGoogle Scholar
  46. 46.
    Sleigh J, Harvey M, Voss L, Denny B (2014) Ketamine—more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care 4:76–81CrossRefGoogle Scholar
  47. 47.
    Storr TM, Quibell R (2009) Can ketamine prescribed for pain cause damage to the urinary tract? Palliat Med 23:670–672CrossRefGoogle Scholar
  48. 48.
    Stotz M, Oehen HP, Gerber H (1999) Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report. J Pain Symptom Manage 18:223–228CrossRefGoogle Scholar
  49. 49.
    Trujillo KA, Akil H (1991) Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85–87CrossRefGoogle Scholar
  50. 50.
    Trujillo KA, Zamora JJ, Warmoth KP (2008) Increased response to ketamine following treatment at long intervals: implications for intermittent use. Biol Psychiatry 63:178–183CrossRefGoogle Scholar
  51. 51.
    US Ketamine clinics continue to mushroom with no regulation. Available at: http://medscape.com. Accessed April 1, 2018.
  52. 52.
    Van Hecke O, Guthrie B (2014) Oral ketamine analgesia in chronic pain and problematic rise in blood pressure. BMJ Case Rep 2014:bcr2014207836CrossRefGoogle Scholar
  53. 53.
    Vranken JH, Dijkgraaf MG, Kruis MR, van Dasselaar NT, van der Vegt MH (2005) Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: a placebo-controlled trial. Pain 118:224–231CrossRefGoogle Scholar
  54. 54.
    Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH (2005) Neuropathological findings after continuous intrathecal administration of S(+) ketamine for the management of neuropathic cancer pain. Pain 117:231–235CrossRefGoogle Scholar
  55. 55.
    Wang L, Johnston B, Kaushal A, Cheng D, Zhu F, Martin J (2016) Ketamine added to morphine or hydromorphone patient-controlled analgesia for acute postoperative pain in adults: a systematic review and meta-analysis of randomized trials. Can J Anaesth 63:311–325CrossRefGoogle Scholar
  56. 56.
    Ward J, Standage C (2003) Angina pain precipitated by a continuous subcutaneous infusion of ketamine. J Pain Symptom Manage 25:6–7CrossRefGoogle Scholar
  57. 57.
    Yaksh TL, Fisher CJ, Hockman TM, Wiese AJ (2017) Current and future issues in the development of spinal agents for the management of pain. Curr Neuropharmacol 15:232–259CrossRefGoogle Scholar
  58. 58.
    Yang CY, Wong CS, Chang JY, Ho ST (1996) Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 43:379–383CrossRefGoogle Scholar
  59. 59.
    Yang L, Zhang J, Zhang Z, Zhang C, Zhao D, Li J (2014) Preemptive analgesia effects of ketamine in patients undergoing surgery. A meta-analysis. Acta Cir Bras 29:819–825CrossRefGoogle Scholar
  60. 60.
    Ye F, Wu Y, Zhou C (2017) Effect of intravenous ketamine for postoperative analgesia in patients undergoing laparoscopic cholecystectomy: a metaanalysis. Medicine (Baltimore) 96:e9147CrossRefGoogle Scholar
  61. 61.
    Zhao J, Wang Y, Wang D (2018) The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and meta-analysis. Curr Pain Headache Rep 22:12CrossRefGoogle Scholar
  62. 62.
    Zhu W, Ding Z, Zhang Y, Shi J, Hashimoto K, Lu L (2016) Risks associated with misuse of ketamine as a rapid-acting antidepressant. Neurosci Bull 32:557–564CrossRefGoogle Scholar
  63. 63.
    Zhu J, Xie H, Zhang L, Chang L, Chen P (2018) Efficiency and safety of ketamine for pain relief after laparoscopic cholecystectomy: a meta-analysis from randomized controlled trials. Int J Surg 49:1–9CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Regional Centre of Excellence in Palliative CareHaukeland University HospitalBergenNorwegen
  2. 2.Perioperative, Intensive Care and Pain MedicineUniversity of HelsinkiHelsinkiFinnland
  3. 3.Pain ClinicHelsinki University HospitalHelsinkiFinnland

Personalised recommendations